The role of Endoplasmic Reticulum stress and GRP78 in endometrial cancer by Conza, Domenico
 
 
UNIVERSITY OF NAPLES “FEDERICO II” 
 
 
 
 
 
DOCTORATE PROGRAM IN 
CLINICAL AND EXPERIMENTAL MEDICINE 
 
Metabolic Endocrine Curriculum 
 
XXIX CYCLE 
 
Coordinator: Prof. Gianni Marone 
 
PHD THESIS 
 
 
 
The role of Endoplasmic Reticulum stress and GRP78 in 
endometrial cancer  
 
 
 
Tutor/Supervisor Candidate 
Ch.mo 
Prof. Pietro Formisano 
 
Dr. Domenico Conza 
 
 
 
TABLE OF CONTENTS  
  
LIST OF ABBREVIATIONS  4 
  
ABSTRACT  6 
  
1. BACKGROUND  7 
  
1.1. Endoplasmic Reticulum Stress  7 
1.1.1. PERK  8 
1.1.2. ATF6  9 
1.1.3. IRE1  10 
1.2. ER Stress and Cancer  11 
1.3. Endometrial Cancer  15 
1.4. Targeting ER stress for cancer therapy  17 
1.5. Metformin  18 
  
2. AIM OF THE STUDY  20 
  
3. MATERIALS AND METHODS  21 
  
3.1. Patients and tissues  21 
3.2. Cell lines and reagents  21 
3.3. Sh-RNA targeting  22 
3.4. Kinetics of cell proliferation and determination  
of cell growth  
 
22 
3.5. MTT assay and Western blot  22 
3.6. Transwell migration assay  23 
3.7. Immunofluorescence  23 
3.8. Biotinylation of cell surface proteins  23 
3.9. Measurement of apoptosis  24 
  
4. RESULTS  26 
  
4.1. mRNA levels of UPR genes are increased  
in endometrioid endometrial carcinoma  
 
26 
4.2. GRP78 protein expression is increased  
in endometrioid endometrial carcinoma  
 
26 
 
 
4.3. The attenuation of GRP78 expression  
inhibits proliferation of endometrial cancer cells  
 
29 
4.4. GRP78 knockdown reduces endometrial cancer cells migration  
and invasion  
 
31 
4.5. AN3CA cells express cell surface GRP78  33 
4.6. An antibody recognizing the C-terminal domain of GRP78  
induces apoptosis of AN3CA but not Ishikawa cells  
 
35 
4.7. The knockdown of GRP78 and the treatment with antibody 
recognizing the C-terminal domain of GRP78  
reduce prosurvival signaling in endometrial cancer cells  
 
 
37 
4.8. GRP78 membrane localization is increased  
in the membrane of endometrial cancer tissues  
 
39 
4.9. Metformin can reduce vitality in endometrial cancer cells  41 
4.10.  Metformin activates the AMPK pathway  
in endometrial cancer cells  
 
43 
4.11. Metformin affect mRNA levels of UPR genes  
in endometrial cancer cells  
 
44 
4.12. Metformin affect protein levels of UPR  
in endometrial cancer cells  
 
44 
4.13. Metformin down regulates β-catenin levels  
in endometrial cancer cells  
 
46 
  
5. DISCUSSION  48 
  
6. CONCLUSIONS  53 
  
7. REFERENCES  54 
  
  
 
 
 
 
4 
 
LIST OF ABBREVIATIONS  
 
 
AMPK:  5' adenosine monophosphate-activated protein kinase 
ASK1: Apoptosis Signal Regulated Kinase 
ATF4: Activating transcription factor 4 
ATF6: Activating transcription factor 6 
BCL2: B-cell lymphoma 2 
BMI: Body Mass Index 
CC: Compound C 
CHOP: C/EBP homologous protein  
EGCG: Epigallocatechin-3-gallate 
eIF2α: Eukaryotic Initiation Factor 2  
EMT: Epithelial mesenchymal transition 
ER: Endoplasmic reticulum 
ERAD: ER Associated Degradation 
ERSE: ER stress response element 
FBS : Fetal bovine serum 
FIGO: International Federation of Gynecology and Obstetrics  
GRP78: 78 kDa glucose-regulated protein 
GRP94: 94 kDa glucose-regulated protein 
HSP72: Heat Shock protein 72 kDa 
HSP90 Heat Shock protein 90 kDa 
IRE1: Inositol-Requiring Enzyme 1 
JNK: c-Jun N-terminal kinase 
5 
 
MAPKKK: Mitogen-Activated Protein Kinase Kinase Kinase 
NF-κB: Nuclear Factor kappa-light-chain-enhancer of activated B cells 
PARP: Poly (ADP-ribose) polymerase 
PDI: Protein disulfide isomerase 
PERK: Protein kinase RNA-like Endoplasmic Reticulum Kinase 
PI3K: Phosphatidylinositol-4,5-bisphosphate 3-kinase 
SCR: Scramble Sequence 
SERCA: Sarco/Endoplasmic Reticulum Ca2+-ATPase 
ShRNA: short hairpin RNA 
T2DM: Diabetes mellitus type 2 
TGFβ: Tumor Growth Factorβ  
TLR: Toll Like Receptor 
TRAF2: TNF-Receptor-Associated Factor 2 
UPR: Unfolded Protein Response 
VEGF: Vascular Endothelial Growth Factor 
XBP1: X-box Binding Protein 1 
 
 
 
6 
 
ABSTRACT  
 
 
Endometrial cancer is the most common malignancy of the female 
genital tract. However, in spite of a huge advance in our understanding of 
endometrial cancer biology, therapeutic modalities haven't significantly 
changed over the past 40 years. Recent studies have indicated that endoplasmic 
reticulum stress, the unfolded protein response activation and altered GRP78 
expression can play an important role in a variety of tumors development and 
progression. Our previous studies reported for the first time that GRP78 is 
increased in endometrial tumors. 
In this study, we further analyzed the role of UPR and GRP78 in 
endometrial cancer progression. We found that GRP78 plays a role in 
endometrial cancer progression since its silencing attenuate both the growth 
and invasion of endometrial cancer cells. Interestingly, we also show that 
metformin, an antidiabetic drug with anticancer properties, is able to inhibit 
endometrial cancer cells growth and this is accompanied by the inhibition of 
GRP78 expression and upregulation of proapoptotic UPR genes such as ATF4 
and CHOP. Finally, we describe that metformin affects β-catenin signaling, a 
frequently activated signaling pathway in endometrial cancer. These 
observations highlight the possibility that GRP78 might represent an intriguing 
therapeutic target of metformin action in the treatment of endometrial cancer. 
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1. BACKGROUND  
 
 
1.1.Endoplasmic Reticulum Stress  
 
In eukaryotic cells, the endoplasmic reticulum (ER) is an essential 
organelle for calcium storage and lipid synthesis. Furthermore, it is the site for 
synthesis, folding and post-translational modifications of cargo proteins1. 
The maturation of nascent proteins in the endoplasmic reticulum is 
monitored by multiple disulfide isomerases (eg. PDI), that catalyze the 
disulfide bonds formation, and a functional class of protein families, calcium-
dependent "molecular chaperones" (as GRP78, GRP94 and calreticulin), which 
are associated with the newly synthesized proteins in order to prevent 
aggregation and enable their correct folding in both physiological and 
pathological conditions2. Therefore, the ER is a quality control system to 
ensure that only properly folded and functional proteins can be released from 
the ER and reach their final destination, while misfolded or inoperative 
proteins are retained in the ER and retrotranslocated in the cytosol for 
degradation by the 26S proteasome through the ER Associated Degradation 
(ERAD) machinery. 
Numerous environmental, physiological and pathological insults, as 
well as nutrient fluctuations, can affect the ER protein-folding environment 
causing accumulation of misfolded proteins, a condition known as ER stress. 
The formation of protein aggregates is toxic to cells and is the 
biochemical basis of many pathophysiological conditions such as ischemia, 
neurodegenerative diseases, diabetes and cancer3. 
To cope with the deleterious effects associated to ER stress, cells have 
evolved a system of homeostatic responses known as Unfolded Protein 
Response (UPR). This complex cellular response is mediated by the activation 
of three ER transmembrane proteins that act as sensors of ER stress: Pancreatic 
ER kinase (PERK), Activating Transcription Factor 6 (ATF6) and Inositol-
Requiring Enzyme 1 (IRE1).  
In the absence of ER stress, these proteins are maintained in an inactive 
state through their association with the chaperone molecule Glucose Regulated 
Protein 78 (GRP78). On the contrary, when ER stress and, thus, accumulation 
of misfolded proteins occurs, GRP78 dissociates from the three sensors 
determining their activation and inducing the UPR (Fig. 1).  
The UPR, by attenuating the general translation process, upregulating 
the transcription of genes encoding for ER chaperones and folding enzymes 
and enhancing the degradation of malfolded proteins by the ERAD machinery 
tries to alleviate ER stress. Depending on the persistence and severity of ER 
stress, the UPR can ultimately result in cell death through the activation of 
apoptotic pathways specifically mediated by the ER, as well as coupling with 
the mitochondrial pathways4. 
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Fig. 1. The response to stress mediated by the UPR. The GRP78 protein dissociates 
from the three ER stress sensors (ATF6, PERK and IRE1) causing their activation. 
PERK is the first to be activated followed by ATF6 while IRE1 is activated only later. 
ATF4 and ATF6 mediate transcription of CHOP, while IRE1 splices XBP1 mRNA 
(sXBP1) generating an active transcription factor that translocates to the nucleus 
activating the transcription of chaperones and P58IPK to restore the endoplasmic 
reticulum function3. 
 
1.1.1. PERK 
 
PERK is a type I transmembrane kinase which is activated by the 
dissociation of GRP78 by its luminal domain with subsequent dimerization and 
autophosphorylation of the protein.  
Upon activation, PERK determines Ser51 phosphorylation of the 
translation initiation factor eIF2α (eukariotic translation initiation factor 2α), 
which regulates the attack initiator Met-tRNA to the ribosome, thus resulting in 
the inhibition of protein translation5. This event promotes cell survival by 
inhibiting further accumulation of nascent proteins in the ER.  
Since eIF2α is the direct substrate of the kinase PERK the block of 
protein translation occurs almost immediately6.  
However, by means of still poorly known mechanisms, some mRNAs, 
such as that coding for the transcription factor ATF4 (activating transcription 
factor 4), is able to evade this translational block4 (Fig. 1). ATF4 promotes cell 
survival via activation of genes involved in amino acid metabolism, redox 
reactions, and protein secretion7.  
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ATF4 also activates the transcription of C/EBP homologous protein 
(CHOP; also known as DDIT3 and GADD153)8, which is required for ER-
stress-mediated apoptosis both in vitro and in vivo9. Initially, PERK activation 
represses CHOP transcription through miR-211 expression and histone 
methylation10. Under conditions of severe or chronic stress, constitutive PERK-
mediated phosphorylation of eIF2α leads to apoptosis, as the prosurvival 
IRE1α–XBP1 and ATF6α pathways are attenuated11,12. It is likely that the 
particular response differs between cell types and environments on the basis of 
different ‘thresholds’ for ER stress tolerance of the cell. Although CHOP 
accumulation in the cell correlates with cell death, both ATF4 and CHOP 
mRNAs and proteins have short half-lives; therefore, a strong and chronic 
activation of PERK is necessary to increase steady state levels of CHOP to 
promote cell death11. Therefore, PERK activation promotes both adaptive as 
well as apoptotic responses depending on the severity of the stress.  
 
1.1.2. ATF6 
 
In mammals, the ATF6 sensor is present in two isoforms, called ATF6α 
(90 kDa) and ATF6β (110 kDa). ATF6 is a type II transmembrane 
glycoprotein, whose luminal domain is responsible for the detection of 
misfolded proteins. The cytoplasmic portion of ATF6 is able to act as a 
transcriptional factor in that it contains a DNA binding domain. Following its 
dissociation from GRP78, ATF6 translocates to the Golgi apparatus, where it 
undergoes a proteolytic cleavage at the level of its iuxta membrane domain, by 
the serine proteases S1P and S2P, generating an active transcription factor13 
(Fig. 1). ATF6 in its active form may therefore translocate into the nucleus, 
where it induces the transcription of target genes that possess in their promoter 
region ER stress response element/s (ERSE)14. Among the genes regulated by 
ATF6, have been identified those coding for some protein chaperones such as 
GRP78, GRP94 and PDI as well as other such GADD153/CHOP and the X-
box binding protein 1 (XBP1). ATF6α mediates also the adaptive response to 
ER protein misfolding by upuregulating the transcription of genes tha increase 
ER capacity and ERAD 15,16, whereas ATF6β may function as a repressor of 
ATF6α-mediated transcription and function17. At present, no genes have been 
identified that require ATF6β for their expression. PERK–eIF2α signaling 
facilitates ATF6α synthesis and trafficking to enhance ATF6α signaling18. To 
date, no substantial evidence supports a role for ATF6α in ER stress-induced 
apoptosis.  
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1.1.3. IRE1  
 
IRE1 is a sensor with dual enzymatic activity, as it has both a serine-
threonine kinase domain and endoribonuclease domain19. 
Under non-stress conditions, the proteins HSP90 and HSP72 bind the 
IRE1α cytosolic domain to maintain its stability20,21, while GRP78 binds the 
luminal domain of IRE1α to prevent dimerization. Upon ER stress, unfolded 
and misfolded proteins bind and sequester GRP78, thereby releasing IRE1α for 
oligomerization, autophosphorylation and activation of its kinase and 
endoribonuclease activities22,23.  
IRE1 catalyzes the unconventional splicing of 26 nucleotides from the 
mRNA encoding, the X-Box Binding Protein-1(XBP1)15, determining a frame-
shift and generating protein with the original N-terminal DNA-Binding 
Domain and an additional transactivation domain at the C-terminus24,25. The 
resulting protein (sXBP1) encodes a transcription factor stable and active. 
sXBP1 translocates to the nucleus where it determines the transcription of 
genes encoding for the ER chaperons, ERAD components and P58IPK, a 
member of the family of heat shock protein 40 (HSP40IPK)26. P58IPK is able 
to bind to PERK and, by means of a negative feedback mechanism, removes 
the PERK-mediated translational block27. Forced XBP1s expression inhibits 
CHOP expression, thereby promoting cell survival28. 
Although the activation of IRE1 and splicing of XBP mRNA events 
appear to be more involved in cell survival, since they determine the induction 
of the transcription and synthesis of GRP78, GRP94, and P58IPK, it has been 
demonstrated that they can play a role in apoptosis activation under irreversible 
ER stress conditions29. Such a pro-apoptotic effect of IRE1 is mediated by the 
activation of the JNK kinase30. In particular, IRE1 is be able to recruit the 
adapter molecule TNF-receptor-associated factor 2 (TRAF2) and to activate 
Apoptosis Signal Regulated Kinase (ASK1), a Mitogen-Activated Protein 
Kinase Kinase Kinase (MAPKKK), which can transmit the death signal to the 
MAPKs JNK and p3831. Once activated, JNK is responsible for the 
phosphorylation of bcl2 abolishing its anti-apoptotic activity. Furthermore, it is 
also able to determine the phosphorylation of the pro-apoptotic BH3/BIM 
protein, enhancing its pro-apoptotic effect32. Thus, in presence of ER stress, 
activation of IRE1 play a critical role in the initiation of pro-apoptotic signals, 
while the activation of PERK and ATF6 sensors appears to precede the 
activation of IRE1 in the attempt to resolve the situation to the ER stress. If the 
stress persists, the PERK and IRE1 pathways can converge, mediating the 
induction of apoptosis through a mutual enhancement. 
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1.2.ER Stress and Cancer  
 
Recently, much research in oncology has revealed that ER stress and 
UPR activation play a crucial role during the process of carcinogenesis. 
Therefore, they were recognized as critical processes in the biology of cancer 
cells as responsible for the maintenance of the malignant phenotype and 
acquisition of chemoresistance1. Tumor cells, which proliferate rapidly, require 
indeed an increased activity by the ER, to facilitate the folding, assembly and 
transport of secretory and membrane proteins. In contrast, normal cells are not 
subject to ER stress and the UPR is mainly in an inactive state (Fig. 2A). At the 
same time, tumor cells experience unfavorable conditions, due to an inadequate 
blood supply, such as hypoxia and nutrient deprivation. An inadequate supply 
of glucose influences both the process of protein glycosylation and production 
of ATP molecules, contributing to the accumulation of incorrectly folded 
proteins resulting in ER stress (Fig. 2B). Consequently, the UPR activation has 
been observed in several tumors types1. 
UPR activation protects cancer cells from stress-induced cell death33-35. 
Acute UPR activation enhances the protein folding capacity to meet the need 
for increased protein synthesis, which benefits cancer cell survival. Where 
chronic ER stress kills normal cells, tumor cells use strategies that neutralize 
apoptosis when challenged with ER stress. In response to chronic stress, 
normal cells usually attenuate the IRE1α–XBP1 and ATF6α pathways, so that 
the apoptotic signals dominate36. Some cancer cells, however, exhibit 
constitutive activation of the IRE1α–XBP1 pathway37,38 or overexpression of 
GRP78 39,40, which are anti-apoptotic.  
During tumorigenesis, the marked increase in the levels of GRP78 and 
other chaperones of the ER by the UPR can improve the ER ability to folding 
and help to maintain homeostasis. In addition, the anti-apoptotic properties of 
GRP78 can counteract the cell death signals that are still functional in cancer 
cells. The maintenance of a chronic level of ER stress, through the expression 
of GRP78 and ATF6 would, therefore, be particularly effective in promoting 
growth and tumor progression41. 
Under normal conditions, GRP78 is localized in the ER lumen, but 
upon overexpression, as described in many human cancers, it becomes 
detectable on the cell surface42. GRP78 at the plasma membrane43 can function 
as a multi-functional receptor44, amplifying the PI3K/AKT pathway and 
promoting both proliferation and cell survival. It has been described that 
GRP78 in membrane can form a complex with Cripto protein, contributing to 
the inhibition of the TGF-β pathway, thus promoting the proliferation of cancer 
cells45. GRP78 expression not only correlates with cancer cell proliferation and 
histological grade but also correlates with response to therapies and 
prognosis46. 
ER stress and the UPR activation may promote tumorigenesis in 
various ways (Fig. 3). 
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For example, ER stress promotes angiogenesis by stimulating both 
expression and secretion of VEGF (Vascular Endothelial Growth Factor)47,48 in 
both tumor and endothelial cells.  
In particular, ATF4 and XBP1s can directly bind to the VEGFA 
promoter to initiate VEGFA transcription. VEGFA mRNA stability is also 
increased in response to UPR activation, via activation of AMPK48.  
ER stress and UPR activation, aside from the effects on tumor cell 
survival and proliferation can promote cancer progression also through the 
activation of inflammatory responses.  
All three UPR pathways can indeed lead to the activation of nuclear 
factor-κB (NF-κB), a master transcriptional regulator of pro-inflammatory 
pathways49.  
Recent studies also suggest a role for ER stress in promoting 
macrophage activation and inflammation in the microenvironment of the 
tumor50. 
 Macrophages grown in conditioned medium from tumor cells with ER 
stress become, indeed, stressed and also activated enhancing the 
proinflammatory response of tumor cells, thus favoring tumor progression (Fig. 
3). ER stress in macrophages promotes the type M2 macrophage phenotype51 
that in turn supports tumor growth. In addition, ER stress-induced expression 
of CHOP, in combination with TLR agonists, enhances dendritic cell 
expression of IL-2352 that favours development of T helper 17 (TH17) cell-
mediated inflammation and tumor growth53.  
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Fig. 2. A. In a normal cell under physiological conditions, GRP78 binds the ER stress 
sensors keeping them in a dormant state. B. In a cancer cell, where there is a chronic 
level of ER stress, GRP78 dissociates from ER stress sensors, allowing their transient 
activation. As a consequence, the translation is temporarily reduced and the 
transcriptional activation of stress genes promotes cell survival. C. In case of severe 
ER stress, the apoptotic response, through the activation of CHOP, overwhelms the 
prosurvival response44. 
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Fig. 3. How ER stress and UPR promote tumor progression. Cancer cells undergo 
ER stress due to low oxygen and glucose levels. The adaptive response of the UPR is 
activated to support the survival and growth of cancer cells. In these conditions 
cancer cells secrete pro-angiogenic factors to stimulate the proliferation of 
endothelial cells, which, in turn, promote the survival and growth of the tumor. 
Cancer cells under ER stress also secrete proinflammatory signals to 
microenvironment macrophages that, in turn are activated and secrete inflammatory 
cytokines that further promote tumor growth, angiogenesis, invasion and metastasis. 
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1.3.Endometrial cancer  
 
The uterus is the female organ involved in the development of the 
embryo during pregnancy. It is formed by two main parts: the lower part, 
called the neck or cervix, in direct connection with the vagina, and the upper 
part called the body of the uterus, that is formed by different tissues. 
In the uterine body, the superficial layer, rich in glands is called the 
endometrium, while the internal layer, a muscle tissue type, is called 
myometrium.  
The hormonal changes that occur during the menstrual cycle 
significantly affect the structure of the endometrium which, in case of 
pregnancy, thickens and feeds the embryo, while if pregnancy does not occur, 
it degrades and is expelled through the vagina, in the form of menstrual flow. 
Endometrial cancer is the most common malignancy of the female 
genital tract accounting for 6% of all cancers. 
The main risk factor for endometrial cancer is age. However, risk 
factors include obesity, diabetes, estrogen therapy, polycystic ovarian 
syndrome and westernization of life style54. 
Endometrial carcinomas are classified into Type 1 and Type 2. 
Type 1 endometrial carcinomas are typically estrogen-receptor positive, 
occur in younger women in premenopause and are well differentiated from a 
histological point of view.  
In contrast, type 2 endometrial carcinomas are estrogen receptor 
negative, more common in older women after menopause, moderately to 
poorly differentiated and have poor prognosis55. The most common form of 
endometrial carcinoma is type 1 (endometrioid subtype) 
According to the classification system FIGO (International Federation 
of Gynecology and Obstetrics), endometrial carcinoma is graded as low grade 
(well differentiated) or high grade (poorly differentiated), based on 
histopathology and evaluation of tumor cell morphology.  
In particular:  
G1 well differentiated; 
G2 moderately differentiated; 
G3 poorly differentiated  
Additionally, it can be divided into four stages depending on body 
spreading: 
Stage I: The tumor is limited to the uterus body and does not invade the 
cervix, lymph nodes or other distant sites. 
Stage II: Cancer has spread to the cervix, but does not affect areas 
outside of the uterus. 
Stage III: Cancer has spread beyond the uterus, but is still limited to the 
pelvic region. 
Stage IV: Cancer has spread to the bladder, rectum, pelvic lymph nodes 
and other distant areas as bones or lungs. 
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Fig. 4. A. Female genital. B. Endometrial cancer.  
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1.4.Targeting ER stress for cancer therapy  
 
Chronic ER stress and permanently increased levels of GRP78 
expression provide a survival advantage to tumor cells. However, it may 
represent also an opportunity for therapeutic intervention. It is conceivable that 
therapeutic exploitation of chronic ER stress present in tumor cells could be 
approached from two antagonistic directions, as offered by the yin and yang 
principle of this stress system and the respective key control factors, GRP78 
and CHOP. 
 One obvious approach would entail the blockage of the system's pro-
survival yang function (e.g., GRP78), whereas the complementary tackle 
would be achieved via enhancement of the pro-apoptotic yin process (e.g., 
CHOP and other components)56.  
Several naturally occurring compounds were found to block GRP78 
transcription or inhibit the activity of the protein, such as, the isoflavone 
genistein, the polyphenolic green tea component (−)-epigallocatechin-3-gallate 
(EGCG), the microbial metabolites versipelostatin, prunustatin A, efrapeptin J, 
verrucosidin, deoxyverrucosidin, piericidin A, the plant product arctigenin, the 
cyanine dye pyrvinium and synthetic members of the biguanide class of 
compounds (metformin, buformin, phenformin)56. 
 However, many of these compounds exert additional, well-recognized 
biological functions besides inhibition of GRP78 56. 
 On the other side, several compounds have been described to aggravate 
the ER stress response of tumor cells via enhancement of key regulators of the 
pro-apoptotic arm of the UPR.  
Among them, proteasome inhibitors that aggravate the accumulation of 
superfluous and misfolded proteins, thus leading to chemosensitization 
(bortezomib); antiretroviral protease inhibitors that have been in use for the 
treatment of HIV infections  that with their protease-inhibitory function can 
target the enzymatically active core of the proteasome (nelfinavir); COX-2 
inhibitors that can inhibit also SERCA proteins thus aggravating ER stress 
(celecoxib and derivatives); inhibitors of autophagy such as the classic 
antimalarial compound chloroquine, due to the reciprocal interactions between 
autophagy and ER stress, where blockage of autophagy leads to aggravation of 
ER stress. 
 
 
 
18 
 
1.5.Metformin 
 
Metformin is one of the most widely prescribed oral anti-diabetic 
medications. It is the first line therapy for type 2 diabetes mellitus57. It has an 
anti-hyperglycemic effect which is mediated by inhibiting gluconeogenesis, 
decreasing glucose absorption from the small intestine, increasing glucose 
uptake in cells, and decreasing plasma free fatty acid concentration58. 
Metformin also increases insulin induced translocation of glucose transporters 
to the cellular plasma membrane, thus reducing insulin resistance59. 
Use of metformin has been found to be generally safe, with mild 
gastrointestinal symptoms being the most common adverse.  
Epidemiological studies have demonstrated a correlation between 
T2DM and a higher incidence of malignancies, especially cancers of the liver, 
pancreas and endometrium, with approximately a twofold increased risk, as 
well as cancer of the colon, kidney, bladder and breast, with smaller 
associations (about 1.2–1.5 fold)61.  
Since epidemiologic data have highlighted the positive effects of 
metformin to reduce cancer incidence and mortality, many in vitro and in vivo 
studies, as well as a large number of clinical trials, have been conducted in 
order to study its potential.  
The many anticancer actions of metformin lead to a cytostatic effect. 
Two distinct but not exclusive mechanisms can be implicated in these 
actions62.  
First, by decreasing insulinemia and glycaemia, metformin can block 
the PI3K/MAPK signaling pathway implicated in cell growth.  
Second, metformin can directly act on cancer cells by targeting various 
pathways including tumor metabolism, inflammation, angiogenesis or cancer 
stem cells, mainly through the activation of the AMPK pathway.  
However, an increasing number of studies support the hypothesis that 
antineoplastic action of metformin can be exerted also through different and 
AMPK-independent mechanisms. 
It has been described, indeed, that metformin decreases the expression 
of the oncoprotein HER2 (erbB-2) in human breast cancer cells via a direct 
inhibition of p70S6K1 (p70 S6 kinase 1) activity63. 
Furthermore, metformin has been described to suppress epithelial to 
mesenchymal transition (EMT), a key developmental program that is often 
activated during cancer invasion and metastasis64. 
Very recently it has been suggested that metformin can inhibit the UPR. 
Using gene expression profiling techniques, it has been reported indeed that 
metformin is able to inhibit activators of the UPR and lead to massive cell 
death in glucose-deprived cultures of human colon, fibrosarcoma, renal, and 
stomach cancer65.  
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Fig. 5. Focus on metformin antitumour activities. Accumulating evidence from in 
vitro and in vivo studies supports the fact that anticancer effects of metformin can be 
divided into two non-exclusive categories: an indirect effect by reducing the blood 
glucose and insulin levels, and a direct effect on cancer cells, partially through the 
activation of AMPK62 .  
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2. AIM OF THE STUDY 
 
 
Endometrial cancer is the most common malignancy of the female 
genital tract. However, in spite of a huge advance in our understanding of 
endometrial cancer biology, therapeutic modalities haven't significantly 
changed over the past 40 years. There is an increasing interest in the 
characterization of the molecular mechanisms involved in this pathology, to 
identify new molecules that could be used, also in association with currently 
used therapeutic agents, for the treatment of the disease. The aim of this study 
was to analyze the role of ER stress and the modulation of the UPR in 
endometrial cancer. 
Furthermore, since multiple lines of evidence suggest that metformin 
exerts anti-tumorigenic effects in different types of cancer, including 
endometrial cancer, we sought to investigate whether metformin could exert its 
anticancer activity on endometrial cell through the modulation of the UPR. 
 The results achieved by this project may represent a good starting point 
to develop novel therapies for the treatment of this tumor. 
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3. MATERIALS AND METHODS 
 
 
3.1.Patients and tissues 
 
Endometrial cancer tissue biopsies (N=12) were collected from women 
undergoing total abdominal hysterectomy for endometrioid endometrial 
carcinoma at the Department of Obstetrics and Gynecology of University of 
Naples “Federico II”. All tissues were examined and tumors were graded 
histologically by a specialist gynecological pathologist according to the 
guidelines of the International Federation of Gynecology and Obstetrics. 12 
patients, matched for age, BMI, and parity, who were undergoing a total 
abdominal hysterectomy for benign conditions, were used as controls. Vaginal 
and cervical swabs were performed 2 weeks before the surgical treatment and 
did not reveal any sign of cervical and/or vaginal infections in any patient. All 
endometrial specimens collected during surgical procedures were stored at −70 
°C. All patients signed an informed consent to participate in the study, which 
was approved by our Institutional Review Board. The main clinical and 
anthropometric characteristics of the enrolled patients are reported in Table 1. 
 
3.2.Cell lines and reagents 
 
The human endometrial cancer cell lines used were Ishikawa (kindly 
provided by Prof. S. Catalano, Department of Pharmaco-Biology, University of 
Calabria, Arcavacata di Rende, Italy), derived from well-differentiated 
endometrial adenocarcinoma, HEC1B (provided by Dr. E. Crescenzi, IEOS-
C.N.R.) derived from moderately-differentiated endometrial adenocarcinoma 
and AN3CA (kindly provided by Dr. S. Petrosino, Institute of Biomolecular 
Chemistry of C.N.R., Pozzuoli, Italy), derived from undifferentiated 
endometrial adenocarcinoma. Ishikawa and HEC1B cells were grown in 
DMEM supplemented with 10% fetal bovine serum and 300 mM L-glutamine, 
in a humidiﬁed atmosphere with 5% CO2. AN3CA were grown in MEM 
supplemented with 10% fetal bovine serum (FBS) and 300 mM L-glutamine, in 
a humidiﬁed atmosphere with 5% CO2. DMEM, MEM, L-glutamine, FBS, and 
G418 were from Lonza (Verviers, Belgium). MTT (3-(4,5- dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) dye and tunicamycin were purchased 
from Sigma (St. Louis, MO). Transwell plates were from Corning (Acton, 
MA). The anti- GRP78 antibody recognizing the N-terminal domain, the anti-
GRP78 recognizing the C-terminal domain of the protein, anti ATF6, anti 
ATF4, anti-CHOP, anti eIF2α, anti-β-actin, anti-p53, anti-PARP, anti-cleaved 
caspase 9, anti-14-3-3, anti-AKT, anti-p-AKT, anti-ERK1/2, anti-p-ERK1/2, 
anti AMPK, anti p-AMPK, anti p-S6K, anti β-catenin, anti p-GSK3β and anti 
PKCα antibodies were from Santa Cruz Biotechnologies (Dallas, TX).  
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The Cell Surface Protein Isolation Kit and the Enhanced 
chemiluminescence Western blotting detection reagents were purchased from 
Pierce Biotechnology (Rockford, IL). 
 
3.3.Sh-RNA targeting 
 
To inhibit expression of endogenous GRP78, cells have been stably 
transfected with either constructs containing short hairpin (sh)-RNA speciﬁc to 
human GRP78 or a scrambled sh- RNA with no homology to any known 
human mRNA, as negative control (Qiagen, Valencia, CA). Positive cells have 
been then selected by treating cells with 600 mg/ml G418. 
 
3.4.Kinetics of cell proliferation and determination of cell growth 
 
Untransfected cells, cells stably transfected with a construct carrying a 
scramble sequence (Scr) or a sequence speciﬁc to human GRP78 (sh) were 
seeded at a density of 2 x 104 cells in 12-well plates in 1 ml of culture medium 
supplemented with 10% FBS. After 24, 48, 72, or 96 h, non-adherent cells 
were removed by gentle washing with PBS whether adherent cells were 
detached by trypsin treatment and counted using a standard counting chamber 
Neubauer. 
 
3.5.MTT assay and Western blot 
  
In vitro proliferation was assessed with tetrazolium salt 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Brieﬂy, 1000 
cells of each cell type (transfected or parental) were plated per well onto 96-
well microtiter plates in medium with 10% FBS. One plate was developed 
immediately after cells had adhered (at approximately 4 h), and other plates 
were developed every 24 h for 4 days. Assays were done by incubating each 
plate with 20 ml of MTT substrate for 2 h followed by removal of medium and 
addition of 200 ml of dimethylsulfoxide. Plates were red at a wavelength of 
570 nm. For Western blot assays, cells were washed with ice-cold phosphate-
buffered saline (PBS) and harvested in Laemmli buffer (with b-
mercaptoethanol) containing a mixture of phosphatase inhibitors (0.5 mM 
sodium vanadate, 2 mM sodium pyrophosphate, 5 mM b-glycerolphosphate, 
and 50 mM sodium ﬂuoride) to prevent postlysis dephosphorylation. 
Densitometric analysis was performed on a Macintosh computer using 
the public domain NIH Image J program (developed at the U.S. National 
Institutes of Health; available at http://rsb.info.nih.gov/nih-image/). 
Wound healing assay. Cells (1 x 106 per well) were seeded in six-well 
plates and allowed to adhere for 24 h. Conﬂuent monolayer cells were 
scratched by a 200 ml pipette tip and then washed three times with PBS to 
clear cell debris and suspension cells. Fresh medium was added, and the cells 
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were allowed to close the wound for 48 h. Photographs were taken at 0, 24, and 
48 h at the same position of the wound. 
 
3.6.Transwell migration assay 
 
Cells (2 x 105) were resuspended in 200 µl of serum-free medium and 
seeded on the top chamber of the 8 mm pore, 6.5 mm polycarbonate transwell 
ﬁlters. The full medium (600 µl) containing 10% FBS was added to the bottom 
chamber. The cells were allowed to migrate for 24 h at 37°C in a humidiﬁed 
incubator with 5% CO2. The cells attached to the lower surface of membrane 
were ﬁxed in 4% paraformaldehyde at room temperature for 30 min and 
stained with hematoxylin, and the number of cells on the lower surface of the 
ﬁlters was counted under the microscope. A total of 5 ﬁelds were counted for 
each transwell ﬁlter. 
 
3.7.Immunoﬂuorescence 
 
Tissue sections were deparaffinized and hydrated through xylenes and 
graded alcohol series followed by antigen retrieval in sodium citrate buffer 
[0.01 M (pH 6.0)]. Sections were microwaved for 15 min, washed in PBS and 
PBS containing 0.2% Triton X-100 for 5 min, and incubated for 1 h with 
blocking buffer. 
Tissue sections were incubated o.n. at 4°C with the home made GRP78 
anti-serum diluted 1:250 in blocking buffer. AN3CA and Ishikawa cells grown 
on glass coverslips were ﬁxed with IHC Zinc ﬁxative (BD Pharmingen, San 
Diego CA) at 4°C for 48 h and then treated without any permeabilization. 
Nuclei were stained with 5 mM of the DNA intercalator DRAQ5 (Alexis 
Corporation, Lausen, Switzerland), present in PBS with 50% Glycerol 
mounting medium. Immunoﬂuorescence analysis was performed at a confocal 
laser scanning microscope LSM 510 Meta (Zeiss). The lambda of the argon ion 
laser was set at 488 nm, that of the HeNe laser was set at 633 nm. Fluorescence 
emission was revealed by BP 505–530 band pass ﬁlter for Alexa Fluor 488 and 
by 615 long pass ﬁlter for DRAQ5. Double staining immunoﬂuorescence 
images were acquired separately in the green and infrared channels at a 
resolution of 1024 x 1024 pixels, with the confocal pinhole set to one Airy unit, 
and then saved in TIFF format. Fluorescence intensity analysis was performed 
on a Macintosh computer using the public domain NIH Image J program 
(developed at the U.S. National Institutes of Health; available at 
http://rsb.info.nih.gov/nih-image/). 
 
3.8.Biotinylation of cell surface proteins 
 
Biotinylation of cell surface proteins was performed using the Cell 
Surface Protein Isolation Kit (Pierce   Biotechnology). Brieﬂy, four T75 ﬂasks 
of AN3CA cells were grown to 95% conﬂuency, washed twice with ice-cold 
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PBS and incubated in 0.25 mg/ml EZ-Link Sulfo-NHS-SS-Biotin for 30 min at 
4°C with rocking. Following saturation with quenching solution, the cells were 
scraped, pelleted at 500 g for 3 min, and washed several times with TBS. Cells 
were lysed in 500 ml of lysis buffer for 30 min on ice with vortexing every 5 
min. The lysates were centrifuged at 10000 x g for 2 min at 4°C, and the 
biotinylated proteins were isolated from the cleared supernatant by binding to 
immobilized NeutrAvidin slurry for 60 min at room temperature with rotation. 
The slurry was washed four times with wash buffer containing protease 
inhibitors, and the biotinylated proteins were solubilized in 400 ml of 4x SDS– 
PAGE sample buffer (50 mM Tris, pH6.8, 2% SDS, 10% glycerol, 0.01% 
bromophenol blue, and 50 mM DTT) for 60 min at room temperature with 
rotation. As a control, total cell lysates were collected in SDS–PAGE sample 
buffer. Immunoblot analysis was used to identify target proteins of interest in 
both total and cell surface lysates. Densitometric analysis was performed on a 
Macintosh computer using the public domain NIH Image J program (developed 
at the U.S. National Institutes of Health; available at http://rsb.info.nih.gov/nih-
image/). 
 
3.9.Measurement of apoptosis 
 
Apoptosis was assessed by staining of cell membrane-exposed 
phosphatidylserine with ﬂuorescein isothiocyanate-conjugated Annexin V 
according to the manufacturer’s description (BD Pharmingen). Samples were 
analyzed by ﬂow cytometry using a FACSCalibur (Beckman Instruments, 
Fullerton, CA), equipped with CellQuest Analysis Software. 
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Table 1.  
Clinicopathological characteristics of analyzed endometrial carcinoma  
 
Paziente Età 
(anni) 
BMI 
(kg/m2) 
FIGO 
(stadiazione) 
FIGO 
(gradazione) 
1 54 36 IA G1 
2 55 37 IA G2 
3 55 42 IA G2 
4 49 23 IA G1 
5 49 30 IA G1 
6 55 45 IA G1 
7 55 33 IA G2 
8 50 40 IA G1 
9 54 35 IA G2 
10 52 28 IA G1 
11 57 34 IA G1 
12 53 33 IA G2 
Controlli (n=12) 52±3 25±3 Nd nd 
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4. RESULTS 
 
 
4.1.mRNA levels of UPR genes are increased in endometrioid 
endometrial carcinoma  
 
Since it has been described that ER stress is activated in different types 
of cancer1,35,38,47, we hypothesized that ER stress might be activated also in 
endometrial cancer. To test this hypothesis, we collected, 12 tissue samples 
from endometrial tumors GI stadium and grade G1/G2 and 12 samples of 
endometrial healthy tissue. The histopathological features of these samples, 
along with age and body mass index (BMI) of patients, are listed in Table 1.  
We analyzed mRNA expression levels of genes activated during the 
UPR in tissue specimens of endometrioid endometrial carcinoma. As shown by 
Real-Time RT-PCR experiments, mRNA expression levels of GRP78 and 
ATF6 were significantly increased in endometrioid endometrial carcinomas 
when compared to that of normal endometrium (Fig. 6A), suggesting the 
presence of ER stress and UPR activation in endometrial cancer.  
 
4.2.GRP78 protein expression is increased in endometrioid 
endometrial carcinoma  
 
To strengthen the Real-Time RT-PCR data, we analyzed GRP78 and 
ATF6 protein expression in the same tissues. As shown by Western blot 
experiments (Fig. 6B), also GRP78 and ATF6 protein expression levels were 
significantly increased, confirming the activation of UPR in endometrioid 
endometrial carcinomas. Moreover, an immunohistochemical analysis was 
performed. Tissues of Table 1 were stained with anti-GRP78 antibodies.  
A mild staining for GRP78 protein (score 1.3±0.3) was detected in 
normal endometrial cells, as shown by normal glandular cells of control tissues 
C2 and C3 (Fig. 7 panels B and C, respectively), whereas glandular and 
luminal neoplastic epithelial cells from G1–G2 endometrioid endometrial 
carcinomas K10 and K3 showed a strong (score 3.2±0.6) or a moderate (score 
2.3±0.5) increased expression of Grp78 (Fig. 7 panels D and E–F, 
respectively), correlating with their GRP78 content, previously observed by 
Western blot experiments. In particular, Grp78 was abundantly present in all 
epithelial tumor cells with a membrane and a cytoplasmic localization (D–F). 
Median value for control specimens (n=12) scored 0.9±0.4 (p<0.05) whereas 
that for endometrioid endometrial carcinomas (n=12) scored 2.7±0.6 (p<0.05) 
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Fig. 6. ER stress markers are upregulated in endometrial adenocarcinoma. A. 
Real-Time RT-PCR analysis of total RNA isolated from tissue specimens of control 
patients (n=12) with benign conditions and patients (n=12) undergoing surgical 
treatment for endometrial carcinoma. Each bar represents the mean±s.d. of four 
independent experiments, each performed in triplicate. (REU, relative expression 
units). Asterisks indicate statistically significant differences (**, P<0.01).B. GRP78 
protein expression is increased in endometrioid endometrial adenocarcinoma. 
Western blots of total protein extracts from 12 normal (C) and 12 endometrioid 
endometrial carcinoma specimens (K). Filters were probed with antibodies against 
GRP78 (home-made antibodies), ATF6 and β-actin. The graphs show GRP78 (left 
panel) and ATF6 (right panel) protein expression levels. Values shown represent the 
mean (±s.d.) of three independent experiments. ***, P<0.001. 
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Fig. 7. Immunohistochemical expression for Grp78 in normal endometrium and 
in Stage I G1–G2 endometrioid endometrial adenocarcinomas. A. Negative 
control was obtained using commercial mouse IgG (IHC×106). B–C. Mild expression 
of Grp78 in normal endometrial glands (Hematoxylin and eosin×106). C2 (B) and C3 
(C) samples are shown. D. Well-differentiated endometrioid endometrial carcinoma 
(G1) showing a huge cytoplasmic immunoreactivity (IHC×106). K10 is shown. E–F. 
Moderately differentiated endometrial carcinoma (G2) showing a moderate 
cytoplasmic and membrane positivity of the neoplastic cells (IHC×106). K3 is shown. 
A high power field is seen in F (IHC×400). Homemade GRP78 antibodies have been 
used. 
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4.3.The attenuation of GRP78 expression inhibits proliferation of 
endometrial cancer cells  
 
GRP78 is reported to play a role in the growth of different tumors. 
Therefore, we hypothesized that GRP78 might play a role also in endometrial 
cancer cells growth. To explore the role of GRP78 in the regulation of cell 
growth in endometrial cancer, we examined the proliferation rate of both 
AN3CA and Ishikawa cells untransfected or stably transfected with vectors 
containing either a scramble short hairpin sequence (Scr) or short hairpin 
sequences specific to GRP78 (Sh1-4).  
As shown in Figure 8, at variance with the scramble sequence, all the 
short hairpin sequences targeting GRP78 were able to decrease GRP78 protein 
level in both AN3CA (A) and Ishikawa cells (B), albeit with different efficacy. 
Interestingly, cell proliferation, evaluated by proliferation curves analysis, of 
both AN3CA (C) and Ishikawa cells (D) transfected with Sh was significantly 
decreased when compared to untransfected cells or cells transfected with the 
Scr sequence. Analysis of cell viability performed by MTT confirmed these 
observations in both AN3CA (E) and Ishikawa cells (F), suggesting that 
GRP78 might play a role in endometrial cancer cells growth. 
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Fig. 8. The attenuation of GRP78 expression inhibits proliferation of endometrial 
cancer cells. Western blots of total protein extracts from AN3CA (A) or Ishikawa cells 
(B) untransfected or stably transfected with a construct carrying a scramble sequence 
(Scr.) or four different sequences specific to human GRP78 (Sh1-4). Filters were 
probed with antibodies against GRP78 (home-made antibodies) and β-actin. Data 
represent mean values ±SD of triplicate samples of three independent experiments. * 
indicates a P-value <0.05. AN3CA (C) or Ishikawa cells (D) untransfected or stably 
transfected with a construct carrying a scramble sequence (Scr.) or two different 
sequences specific to human GRP78 were plated at a density of 2x104 cells. After 24, 
48, 72, and 96 h, cells were counted using a Neubauer chamber. Data represent mean 
values ±SD of triplicate samples of three independent experiments.*** indicates a P-
value <0.001. AN3CA (E) or Ishikawa cells (F) untransfected or stably transfected 
with a construct carrying a scramble sequence (Scr.) or a short hairpin sequence 
specific to human GRP78 (Sh3 or Sh1 respectively), were seeded at a density of 5x103 
cells in a 96 well plate and cell viability was measured 24, 48, 72, and 96 h later using 
the MTT assay. Values represent the mean absorbance at 540nm ±SD of triplicates of 
three independent experiments. White bars represent cells transfected with a construct 
carrying a scramble sequence (Scr.); black bars represent cells transfected with the 
short hairpin specific to human GRP78. A value of 100% was given to the cell number 
at time 0. ** indicates a P-value <0.01.  
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4.4.GRP78 knockdown reduces endometrial cancer cells migration 
and invasion 
 
Next, since it has been reported that GRP78 is involved in the invasion 
and metastatic process of tumor cells, we examined whether GRP78 also 
participates in the malignant phenotypes of cell migration and invasion of 
endometrial cancer cells.  
To this aim, we performed wound healing and transwell migration 
assays on both AN3CA and Ishikawa cells untransfected or stably transfected 
with vectors containing either the scramble short hairpin sequence (Scr) or a 
short hairpin sequence speciﬁc to GRP78 (Sh). One of the most effective 
vector in downregulating GRP78 expression was used (Sh1 and Sh3 in AN3CA 
and Ishikawa cells, respectively).  
Monolayer cultures were wounded by a micropipette tip and cell 
migration toward the wounded area was observed.  
As shown in Figure 9, although the two different lines of cells migrated 
at different rates, the Sh transfectants in each line migrated slower toward to 
the wounded area compared with the Scr transfectants. At 48 h, the wounded 
area was almost completely covered by Scr- transfected cells, whereas the Sh-
transfected cells were still moving toward into the area.  
Knockdown of GRP78 thus reduces migration, suggesting a positive 
regulation of this protein in cell migration.  
For the invasion assay, transfected cells were seeded in the upper 
chamber of transwell plates. The number of cells invading the lower chamber 
was determined after 24 and 72 h.  
As shown in Figure 9 B and C, a significant reduction of invading Sh-
transfected cells were found in the lower side of the filter separating upper and 
lower chamber compared with those Scr-transfected at both time point.  
Thus, knockdown of GRP78 expression affected the invasion ability of 
endometrial cancer cells. 
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Fig. 9. GRP78 knockdown reduces endometrial cancer cells migration and 
invasion. A. AN3CA or Ishikawa cells (1 x 106 per well) transfected either with a 
construct carrying a scramble sequence (Scr.) or a short hairpin sequence specific to 
human GRP78 (Sh1 or Sh3 respectively), were seeded in six-well plates and allowed 
to form a cell monolayer for 24 h. Cell layers were wounded with a micropipette tip 
and then incubated in fresh culture medium for up to 48 h. Cell migration toward the 
wounded area was observed, photographed and measured. Results were obtained 
from three separate experiments; *P < 0.05.B. AN3CA or Ishikawa cells (2 x 105 per 
well) transfected either with a construct carrying a scramble sequence (Scr.) or a 
sequence specific to human GRP78 (Sh1 or Sh3 respectively), were seeded in the 
upper chamber of a 24-well plate as described in the Materials and Methods Section. 
The number of cells migrating through the lower chamber were determined after 24 
and 72 h. Each experiment was done in triplicate.C. Representative experiment of (B).  
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4.5.AN3CA cells express cell surface GRP78 
 
A number of studies have identiﬁed GRP78 on the surface of a variety 
of human cancer cells 43-45,66-74. To determine if GRP78 is similarly expressed 
on the surface of endometrial cancer cells, cell surface proteins were isolated 
using a biotin- based technique followed by immunoblotting with anti-GRP78 
antibodies. GRP78 was identiﬁed in both total cell lysates (t-GRP78) and on 
the cell surface of AN3CA cells (s-GRP78), while it was barely detectable on 
the surface of Ishikawa cells (Fig. 10A).  
GRP78 expression and surface localization were signiﬁcantly increased 
following tunicamycin treatment (Fig. 10A) in both Ishikawa and AN3CA 
cells. Consistent with these biochemical ﬁndings, confocal microscopy 
observations confirmed the presence of GRP78 on the cell surface of AN3CA 
cells (Fig. 10B, part A) but not on that of Ishikawa cells (Fig. 10B, part C). As 
observed in the membrane biotinylation studies, tunicamycin was able to 
markedly increase GRP78 membrane localization in both AN3CA and 
Ishikawa cells (Fig. 10B, part B and D, respectively). 
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Fig 10 GRP78 localizes on the cell surface of endometrial cancer cells and ER 
stress further promotes its cell surface localization. A. Detection of cell surface 
GRP78 expression in Ishikawa and AN3CA cells untreated (C) or treated (Tn) with 1 
mg/ml tunicamycin for 24 h.  Cells were biotinylated and labeled proteins were 
isolated as described in the Materials and Methods Section. Representative Western 
blots are shown. s-GRP78 and t-GRP78, surface and total intracellular GRP78, 
respectively. β-Actin served as loading control. The graph represent the results of 
three independent experiments. *P < 0.05. B. AN3CA and Ishikawa cells were not 
treated (A and C, respectively) or treated (B and D, respectively) with 1 µg/ml 
tunicamycin (Tn) for 24 h. Non-permealized cells were fixed and stained by indirect 
immunofluorescence as described in the Materials and Methods Section using the 
GRP78 home made antiserum. Nuclei (in blue) are counterstained with the DNA 
intercalator DRAQ5. Section from confocal Z-stack images shows the increase of 
GRP78 staining on the plasmamembrane after Tn treatment. The green and red lines 
indicate the locations of the front and side views respectively. Scale bar 10 µm. 
Quantification of fluorescent intensity of Grp78 staining is also shown. The graph 
represent the results of three independent experiments;*P < 0.05.  
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4.6. An antibody recognizing the C-terminal domain of GRP78 
induces apoptosis of AN3CA but not Ishikawa cells. 
 
Treatment with antibodies against the carboxy-terminal domain of 
GRP78 has been reported to profoundly inhibit prosurvival signaling pathways 
in prostate cancer cells that display cell surface localization of GRP7867-74.  
We therefore speculated whether these antibodies may affect the growth 
and/or viability of endometrial cancer cells in relationship with their GRP78 
exposition on the plasma membrane.  
As shown in Figure 11A, following 48 hours of treatment with the 
antibodies (+Ab), at variance with Ishikawa cells, AN3CA cells appeared to be 
slowed down in growth when compared to untreated cells (c). 
Moreover, an increased number of floating cells were easily observable 
in antibodies-treated cells (Fig.11A). To confirm this observation, we 
performed MTT assays to analyze cell viability of treated versus untreated cells 
after 24, 48 and 72 hours. As shown in Figure 8B, AN3CA cells treated with 
the antibodies (+Ab) displayed a significant decline in the percentage of 
proliferating cells when compared to untreated cells (Fig. 11B). At variance, 
Ishikawa cells did not show a significant difference in the proliferation rate of 
treated vs untreated cells (Fig.11C).  
To understand if this might be due to an increase of cell death following 
the treatment, we performed flow cytometry analysis with Annexin V on 
AN3CA cells left untreated or treated for 72 hours with the antibodies specific 
to the carboxy-terminal domain of GRP78. As shown in Figure 8D, antibodies-
treated cells showed a high percentage of apoptotic cells (56.5%). These data 
suggest that cell surface GRP78 might play a role in the growth and survival of 
endometrial cancer cells. 
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Fig. 11 An antibody recognizing the C-terminal domain of GRP78 induces 
apoptosis of AN3CA but not Ishikawa endometrial cancer cells. A. AN3CA and 
Ishikawa cells were treated or not for 48 hours with 200 μg/ml of an antibody 
recognizing the C-terminal domain of GRP78. Cells were observed by light 
microscopy and photographed. AN3CA (B) or Ishikawa (C) cells were seeded at a 
density of 5x103 cells per well in a 96 wells plate and treated or not with 200 μg/ml of 
an antibody recognizing the C-terminal domain of GRP78. Cell viability was 
measured 24, 48, and 72 hours later using the MTT assay. Values represent the mean 
absorbance at 540 nm ± SD of triplicates of three independent experiments. White 
bars represent untreated cells whether black bars represent cells treated with the 
antibody. D. AN3CA cells were treated or not with 200 μg/ml of an antibody 
recognizing the C-terminal domain of GRP78 for 72 hours and subjected to annexin V 
staining as outlined in Materials and Methods section.   
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4.7.The knockdown of GRP78 and the treatment with antibody 
recognizing the C-terminal domain of GRP78 reduce 
prosurvival signaling in endometrial cancer cells  
 
Apoptosis in AN3CA cells but not in Ishikawa cells, following 
antibodies treatment, was conﬁrmed also by the cleavage of poly(ADP-ribose) 
polymerase (PARP) and caspase 9, hallmarks of apoptosis (Fig. 12).  
Since it has been described that ligation of cancer cell surface GRP78 
with antibodies directed against its C-terminal domain can promote apoptosis 
in pancreatic cancer cells by up-regulating p5370, we evaluated p53 levels in 
both AN3CA and Ishikawa cells following antibodies treatment. 
 As shown in Figure 12, despite the fact that AN3CA cells express wild 
type p53 weather Ishikawa cells express a mutated inactive form of the protein, 
p53 protein levels did not increase signiﬁcantly in both AN3CA and Ishikawa 
cells following GRP78 antibodies treatment, suggesting that the activation of 
apoptosis was p53-independent.  
Next, to understand the molecular mechanism/s involved in the 
induction of apoptosis caused by the antibody speciﬁc to the C-terminal 
domain of GRP78, we analyzed the phosphorylation levels of AKT and ERK 
proteins, known to be involved in prosurvival signaling.  
As shown in Figure 12, phosphorylation levels of AKT were 
signiﬁcantly downregulated in antibodies treated AN3CA cells when compared 
to untreated cells. At variance, phosphorylation levels of AKT were unchanged 
in Ishikawa cells. Phosphorylation levels of ERK did not vary signiﬁcantly 
following antibody treatment in both cell types (Fig. 12). These data suggest 
that GRP78 localization on the surface of endometrial cancer cells plays a role 
in endometrial cancer cells survival and that this might be mediated through the 
AKT prosurvival signaling pathway.  
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Fig. 12 The treatment with antibodies recognizing the C-terminal domain of 
GRP78 reduces AKT prosurvival signaling in AN3CA but not in Ishikawa 
endometrial cancer cells. AN3CA and Ishikawa cells were left untreated or treated 
for the indicated times with 200 µg/  ml of an antibody recognizing the C-terminal 
domain of GRP78. Cells were harvested, lysed as described in the Materials and 
Methods Section and 50 µg whole-cell lysates were immunoblotted using anti-PARP, 
anti-cleaved caspase 9, anti-AKT, anti-p-AKT, anti- ERK1/2, anti p-ERK1/2, anti-p53, 
and anti-14-3-3 antibodies. Graphs show densitometric analysis of the bands. Results 
were obtained by three separate experiments; *P < 0.05.   
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4.8.GRP78 membrane localization is increased in the membrane of 
endometrial cancer tissues  
 
We have reported that GRP78 is overexpressed in tissue specimens of 
endometrioid endometrial carcinomas. To address the question if GRP78 could 
be localized, besides on the surface of cultured endometrial cancer cells, also 
on the surface of endometrial tissues, we performed immunoﬂuorescence 
studies on tissue specimens of normal endometrium (N), endometrial 
hyperplasia with atypia (HA) or endometrioid adenocarcinomas characterized 
by different grading (G1 or G2). As shown in Figure 13, in non-pathological 
tissue (A) anti- GRP78 antibodies stain prevalently epithelial cells and the 
staining appears to be conﬁned prevalently to the perinuclear region, 
compatible with an ER localization, but also to the plasmamembrane. In the 
endometrial hyperplastic tissue characterized by atypia, the staining of GRP78 
is slightly enhanced in the plasmamembrane (E). In the G1 (I) and G2 (M) 
carcinoma sections the staining of GRP78 protein is signiﬁcantly increased in 
both the cytoplasm and the plasmamembrane region. These observations 
suggest that GRP78 membrane localization is increased in the membrane of 
endometrial cancer tissues.  
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Fig. 13 GRP78 localizes on the membrane of cells of pathological endometrial 
tissues. Confocal microscopy images of human endometrial tissue sections 
representative of normal endometrium (A–D), dysplastic endometrium with atypia (E–
H), G1 (I–L), and G2 (M–P) endometrial tumors were immunostained with a 
polyclonal home made GRP78 anti-serum (A,E,I,M). Nuclei (in blue) are 
counterstained with the DNA intercalator DRAQ5 (B,F,J,N). Hematoxylin and eosin 
staining of the paraffin sections are also shown (D,H,L,P). Scale bar 100µm. 
Fluorescence intensity measurements of Grp78 staining is also shown.   
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4.9.Metformin can reduce vitality in endometrial cancer cells  
 
Since multiple lines of evidence suggest that metformin exert anti-
tumorigenic effects in different types of cancer, including endometrial cancer, 
first of all we evaluated whether metformin could affect endometrial cancer 
cells growth. 
To this aim, we performed MTT assays on Ishikawa, HEC1B and 
AN3CA cells treated with different concentrations of metformin. 
As shown in Figure 15 Metformin inhibits growth in a dose dependent 
manner in all cell lines. The antitumor activity of metformin has been 
hypothesized to be due also through a AMPK-independent pathway. We used 
Compound C (CC), a specific inhibitor of AMPK, in combination with 
metformin, to evaluate the extent of the AMPK-independent effect of 
metformin on the vitality of endometrial cancer cells. As shown in Figure 15, 
the presence of CC did not affect significantly the effect of metformin, 
suggesting the presence also of  AMPK-independent mechanism/s. 
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Fig. 14 Metformin reduces vitality of endometrial cancer cells. Ishikawa, HEC1B 
and AN3CA cells were left untreated or treated for 24 h with 1, 5 or 10 mM metformin 
in the absence or presence of 100 nM CC and cell growth was evaluated by MTT 
assay. The graph represent the median of three different experiments performed in 
triplicate. **p<0.01.  
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4.10. Metformin activates the AMPK pathway in endometrial 
cancer cells 
 
Metformin induces activation (phosphorylation) of AMPK. Once 
activated, AMPK induces the inhibition of the mTOR signaling pathway, which 
results in a lower activation of S6 kinase. Consequently, there is a reduced 
activation of the ribosomal S6 component and, thus, a decrease of protein 
synthesis. It has been described that metformin activates AMPK in different 
cancer cell lines and that this might be the main mechanism through which 
metformin exerts its cytostatic properties62.  
Metformin was effective in activating AMPK in all endometrial cancer 
cell lines, as demonstrated by the increase of p-AMPK levels and decrease of 
p-S6K levels (Fig. 15). furthermore, CC effectively prevented AMPK 
activation by metformin in all endometrial cancer cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 15. Metformin induces AMPK pathway activation in endometrial cancer 
cells. Ishikawa, HEC1B and AN3CA cells were left untreated or treated for 24 h with 
metformin in presence or absence of Compound C. Cells were harvested, lysed as 
described in the “Materials and Methods” section and 50 μg of whole-cell lysates 
were immunoblotted using anti-AMPK, anti-p-AMPK, anti–p-S6K and β-actin 
antibodies. 
 
 
  
p-AMPK 
AMPK 
p-S6K 
β-actin 
Met.         -     -    +   +      -     -    +    +     -    -    +    + 
 CC          -    +    -    +      -    +     -    +     -   +     -    +    
Ishikawa              HEC1B              AN3CA          
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4.11. Metformin affects mRNA levels of UPR genes in endometrial 
cancer cells  
 
Very recently it has been hypothesized that metformin might affect the 
UPR65. 
Thus, we sought to verify whether metformin could modulate the UPR 
in endometrial cancer cells. 
To test this hypothesis, we treated Ishikawa, AN3CA and HEC1B with 
metformin and we analyzed mRNA expression levels of UPR key genes, such 
as GRP78, ATF4, ATF6, sXBP1 and CHOP. As demonstrated by the 
experiments of Real-Time RT-PCR in Figure 16A, the mRNA levels of anti-
apoptotic UPR genes (GRP78, ATF6, XBP1) were decreased, while those of 
proapoptotic UPR genes (ATF4, CHOP) were significantly increased in treated 
samples when compared to untreated samples, suggesting that metformin 
modulates the UPR in endometrial cancer cells.  
Furthermore, CC was unable to prevent the effect of metformin on UPR 
genes in endometrial cancer cells, suggesting that the effects of metformin on 
UPR modulation were at least in part independent from AMPK activation (Fig. 
16A). 
 
4.12. Metformin affects the expression of UPR proteins in 
endometrial cancer cells  
 
To verify whether UPR protein expression levels paralleled those of 
mRNAs, we performed Western blot experiments on protein extracts obtained 
from cells treated as above. As shown in Figure 16B, protein expression levels 
of GRP78, ATF6, XBP1 were significantly decreased while ATF4 and CHOP 
were increased in the samples treated with metformin, similarly to what 
observed in Real Time RT-PCR experiments. Again, treatment with CC did not 
prevent the effect of metformin on UPR proteins expression. 
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Fig. 16. Metformin affect UPR genes in endometrial cancer. A Relative mRNA 
levels of UPR genes (GRP78, ATF6, XBP1, ATF4, CHOP) in Ishikawa, HEC1B and 
AN3CA cells following metformin and Compound C treatment. B. Representive 
Western blots of UPR genes (GRP78, ATF6, ATF4, CHOP, p-eIF2 α) and p-AKT in 
Ishikawa, HEC1B and AN3CA cells  following metformin and Compound C treatment. 
 
 
  
ATF6 
GRP78 
ATF4 
CHOP 
β-actin 
p-EIF2α 
Met.      -        +       +        -        +       +        -       +       + 
 CC       -        -        +        -        -        +        -       -        + 
Ishikawa                 HEC1B                   AN3CA          
p-AKT 
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4.13. Metformin downregulates β-catenin levels in endometrial 
cancer cells  
 
β-catenin is an important protein for the acquisition of several cancer 
hallmarks by tumor cells. Since GRP78 has been desribed to influence β-
catenin protein stability75 and, thus, β-catenin signaling, we sought to verify 
whether the observed decrease of GRP78 expression following metformin 
treatment could affect β-catenin expression in endometrial cancer cells.  
As shown in Figure 17, metformin was, indeed, able to decrease β-
catenin expression levels in all cell lines. β-catenin downregulation was 
associated to a decrease of the inhibitory phosphorylation site of GSK3β, thus 
implicating an increase of the phosphorylation activity of GSK3β on its 
substrate β-catenin and its increased degradation (Fig. 17). Intriguingly, we 
observed also activation of PKCα by the metformin (Fig. 17). PKCα has been 
described to phosphorylate N-terminal serine residues of β-catenin, promoting 
β-catenin degradation76. 
Immunofluorescence experiments shown in Figure 18 apparently 
confirmed this observation in that metformin induced the translocation and, 
thus, activation of PKCα, in the plasma membrane and concomitant 
downregulation of β-catenin in the same compartment. These results suggest 
that GRP78 inhibition by metformin could, in turn, affect also β-catenin 
expression. 
 
 
 
 
 
Fig. 17 Metformin downregulates β-catenin levels in endometrial cancer cells. 
Western blots of p-PKCα, p-GSK3β and β-catenin in Ishikawa, HEC1B and AN3CA 
cells untreated or treated with 5 mM metformin.  
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Fig. 18 Metformin modulates β-catenin and PKCα levels in endometrial cancer 
cells. Confocal microscopy images of endometrial cancer cells HEC1B and AN3CA. 
HEC1B andAN3CA  cells were not treated (control) or treated with 5 mM  metformin. 
Cells were fixed and stained by indirect immunofluorescence as described in the 
“Materials and Methods” section using polyclonal β-catenin (red) and PKCα (green) 
antiserum. Nuclei (in blue) are counterstained with the DNA intercalator DRAQ5. 
Scale bar 20µm.  
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5. DISCUSSION  
 
 
Endometrial cancer has become the most frequent gynecologic 
malignancy in the Western world77-79. Although this type of cancer is 
diagnosed at an early stage in most cases, almost 20% of patients die of their 
disease79. Molecular genetic studies have provided considerable insights into 
the pathogenesis of endometrial carcinoma. Nevertheless, sufficient prognostic 
markers have yet to be established.  
Recent studies have shown that UPR signaling pathway activation 
following ER stress plays an important role in tumorigenesis80. Following 
initiation of malignancy, poor vascularization of the tumor mass leads, indeed, 
to stressful conditions in the tumor microenvironment, including low oxygen 
supply, nutrient deprivation and pH changes.  
These conditions activate a range of cellular stress response pathways, 
including the UPR80, and many ER chaperones and UPR target genes show 
increased expression in human tumor samples.  
The relevance of UPR pathways to the survival strategy of tumors is 
highlighted by the observation that inhibition of UPR adaptive survival 
responses has been shown to induce selective apoptosis in cancer cells and thus 
may be highly efficient for cancer treatment. Tumors that lack PERK activity, 
or compromised in PERK–eIF2α–ATF4 pathways, are small and compromised 
in their ability to translate mRNAs involved in angiogenesis and tumor 
survival81-83. Disabling the Ire1α-XBP-1 arm of the UPR increases the 
sensitivity of tumor cells to hypoxic environment and enhances the apoptotic 
response.  
Recently, an increasing number of studies indicate that, among the 
proteins upregulated following UPR activation, the ER chaperone GRP78, in 
particular, is critical for tumor proliferation, survival, metastases and resistance 
to a wide variety of therapies. In a recent study, we reported for the first time 
that expression of ER stress markers is increased also in tissue specimens of 
endometrioid endometrial carcinomas, the most common type of endometrial 
carcinoma, at both mRNA and protein level as shown by ATF6 and GRP78.  
In this study, we sought to verify the hypothesis that ER stress and the 
ER chaperone GRP78 in particular, might have a role in endometrial cancer 
cells proliferation and/or invasiveness.  
We show, indeed, that the inhibition of GRP78 expression by the use of 
specific sh-RNAs significantly decreases the growth of endometrial cancer 
cells. GRP78 has been implicated as an important player in cancer progression 
by its role in promotion of tumor cell proliferation and survival during ER 
stress that arises in the tumor microenvironment as a result of hypoxia and 
nutrient deprivation84,85. Increased expression of GRP78 has been indeed 
observed in breast, colon, prostate and melanoma cancer cell lines, as well as in 
ex vivo human primary and animal model tissues43. In support of the notion 
that GRP78 is more critically needed for the survival of stressed cells such as 
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cancer, heterozygous GRP78 mice with half of wild-type (WT) GRP78 level 
are comparable to WT siblings in growth and development. However, tumor 
progression is significantly impeded in these mice as exemplified by a longer 
latency period, reduced tumor size, and increased tumor apoptosis86. This is 
consistent with earlier studies showing that GRP78 reduction in xenografts 
inhibited tumor formation and growth.  
Moreover, knockout of GRP78 in prostate epithelium has been reported 
to inhibit prostate cancer formation in mice87. GRP78 may also be important 
for tumor metastasis because it is elevated in metastatic cancer cell lines and 
lymph node metastasis, and knockdown of GRP78 inhibits tumor cell invasion 
in vitro and growth and metastasis in xenografts models84,88 . 
 Accordingly, we show that GRP78 inhibition reduces the migration 
and invasion capability of endometrial cancer cells. The mechanism whereby 
GRP78 promotes growth and metastasis is just emerging. Part of this 
mechanism might be related to the localization of the protein. Although 
traditionally GRP78 is regarded as a ER resident chaperone whose major 
function is to fold and process ER proteins, bind ER Ca2+ and maintain ER 
homeostasis, recent studies have established, indeed, that, in specific cell types 
or when subjected to stress, GRP78 can be located in compartments outside the 
ER, including the cell surface, the cytosol, the mitochondria and the nucleus, 
and it can even be secreted89-91.  
There is evidence for low constitutive surface expression of GRP78 on 
several cell types, including vascular endothelia92,93. 
However, membrane GRP78 has been detected mainly on cancer cells 
where it can act as a multifunctional receptor, activating downstream pro-
proliferative and anti-apoptotic signaling cascades including RAS/MAPK and 
PI3-kinase/Akt45,94-96.  
We used cell surface biotinylation to demonstrate the expression of 
GRP78 on the surface of endometrial cancer cells, a finding consistent with 
other cancer cells. Indirect immunofluorescence confirmed the presence of cell 
surface GRP78.  
Interestingly, AN3CA cells, deriving by an undifferentiated endometrial 
tumor, showed a GRP78 membrane localization that was further increased by 
treatment with tunicamycin, an ER stress inducer. At variance, Ishikawa cells, 
obtained by a well differentiated endometrial tumor showed a clear plasma 
membrane localization only upon stimulation with tunicamycin, suggesting 
that the amount of GRP78 in the plasma membrane might be related to the 
differentiation degree of endometrial tumors.  
To ascertain the latter correlation, we performed immunofluorescence 
analysis of tissue samples representative of different stages of endometrial 
cancer progression. Interestingly we found that GRP78 protein expression 
tended to increase in tissue sections of endometrium characterized by 
hyperplasia with atypia, known to be a precancerous condition, when compared 
to normal tissues. The amount of GRP78 further increased in tissue samples of 
G1 and G2 endometrial tumors and GRP78 localization in the plasma 
50 
 
membrane paralleled the increase of expression observed in pathological 
tissues, supporting the notion that upregulation of cell surface GRP78 might be 
part of a more aggressive phenotype94. A commercial polyclonal antibody 
directed against the C-terminus of GRP78 was reported to induce apoptosis in 
melanoma cells (A375) and prostate cancer cells (1-LN and DU145), but not in 
another prostate cancer cell line, PC-3, where GRP78 expression was 
undetectable on the surface73.  
The proposed mechanism is that this antibody leads to the upregulation 
of p53, inhibition of NF-κB1 and NF-κB2 activation, and suppression of 
Ras/MAPK and PI3K/AKT signaling45,94-96.  
Since we observed that AN3CA cells display also a plasma membrane 
localization of GRP78, we treated cells with a commercial polyclonal antibody 
directed against the C-terminus of GRP78.  
Similarly to what described on melanoma and prostate cancer cells that 
display a plasma membrane localization of GRP78, viability of AN3CA cells 
treated with the antibody directed against the C-terminus of GRP78 was 
significantly decreased, when compared to that of untreated cells, and was 
associated to a marked high percentage of cells undergoing apoptosis.  
As expected, viability of Ishikawa cells, that did not display GRP78 on 
their surface, was not affected by the antibody treatment, indicating that cell 
surface expression of GRP78 in endometrial cancer cells is required for 
observing an effect of antibodies directed against the COOH-terminal domain 
of GRP78.  
Interestingly, at variance with Ishikawa cells, prosurvival PI3K/AKT 
signaling was significantly decreased in AN3CA cells. This is not surprising 
since AKT is constitutively activated in the majority of endometrioid 
endometrial cancers, due to PTEN loss and/or PI3K mutations97. Activated 
AKT initiates a cascade of downstream signaling events, which promote 
cellular growth, metabolism, proliferation, survival, migration, apoptosis, and 
angiogenesis.  
Very recently it has been described that GRP78 contributes to cisplatin 
resistance of different endometrial cancer cell lines and that GRP78 expression 
contributes to chemoresistance through AKT activity98.  
Downregulating GRP78 expression by the use of specific siRNA, was 
able, indeed, to decrease AKT activity and to sensitize endometrial cancer cells 
to apoptosis98. We evaluated also the activation state of ERK, one of the key 
mediator of MAPK prosurvival signaling pathways, but we did not observe any 
significant alteration of its phosphorylation levels upon antibodies treatment in 
both apoptotic AN3CA and non-apoptotic Ishikawa cells.  
Finally, at variance with apoptosis induced by the anti-GRP78 antibody 
in prostatic cancer cells, we did not observe significant variations of the p53 
protein expression levels in AN3CA treated cells. However, it cannot be ruled 
out the involvement of other key mediators of the apoptotic pathway.  
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Thus, these data suggest that down-regulating the levels of cellular 
GRP78 and/or targeting cell surface-associated GRP78, could be of major 
importance in endometrial cancer therapy.  
Metformin is a biguanide drug that is widely used as the first line 
pharmacologic treatment of type 2 diabetes. However, data obtained in both 
cell lines and animal models suggests that metformin, besides its antidiabetic 
action, may exert also anti-tumorigenic effects62.  
Moreover, epidemiological evidence suggest that metformin use lowers 
cancer risk and reduces the rate of cancer deaths among diabetic patients.  
Many of both the systemic indirect and direct effects exerted by 
metformin on cancer cells are thought to be mediated through the activation of 
the AMP-activated protein kinase (AMPK), a regulator of energy metabolism 
usually activated in response to cellular stresses that deplete cellular energy 
levels increasing the AMP/ATP ratio.  
AMPK activation would, in turn, inhibit the mammalian target of 
rapamycin (mTOR), thereby reducing both protein synthesis and proliferation 
of cancer cells. However, the underlying biological mechanisms of metformin 
antineoplastic activity are still largely unknown and it is becoming increasingly 
evident that AMPK activation by itself is insufficient to explain the plethora of 
metformin effects on different types of cancer cells.  Very recently it has been 
hypothesized that metformin might affect the unfolded protein response (UPR).  
It has been recently shown, indeed, through gene expression profiling 
techniques, that metformin is able to inhibit activators of the UPR, leading to 
massive cell death in glucose-deprived cultures of human colon, fibrosarcoma, 
renal, and stomach cancer65.  
Accordingly, metformin has been described to suppress GRP78, a key 
driver of bortezomib-induced autophagy, to enhance the anti-myeloma benefit 
of bortezomib99. Thus, we hypothesized that metformin could affect 
endometrial cancer cells growth, possibly through the modulation of the UPR.  
We show, indeed, that metformin inhibits both cell growth and 
migration in endometrial cancer cells. However, the role of AMPK pathway 
activation does not appear to be essential for metformin action in endometrial 
cancer cells. The presence of CC, an AMPK inhibitor, is not sufficient, indeed, 
to prevent metformin action on this cell type.  
We rather observed a modulation of the UPR. In particular, GRP78 
expression levels, that have been described to protect cancer cells from 
apoptosis when overexpressed, were downregulated, while expression of 
proapoptotic UPR genes, such as ATF4 and CHOP, were upregulated. 
Furthermore, CC was unable to prevent the observed effects on UPR 
modulation by metformin, suggesting that these were, at least in part, 
independent from the activation of the AMPK pathway.  
Finally, since it has been described that GRP78 might affect β-catenin 
pathway, by influencing the stability of the protein75, we started to analyze the 
effect of metformin on β-catenin.  
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Normally, the Wnt/β-catenin pathway controls developmental processes 
and homeostasis, but abnormal activation of this pathway is a frequent event 
during the development of cancer, including endometrial cancer75. The key 
mechanism in regulation of the Wnt/β-catenin pathway is the amino-terminal 
phosphorylation of β-catenin, marking it for proteasomal degradation.  In the 
absence of a Wnt signal, β-catenin forms a complex with adenomatous 
polyposis coli (APC)/Axin and is phosphorylated by a dual-kinase mechanism, 
which is catalyzed by casein kinase 1 (CK1) and GSK-3β, at Ser/Thr residues 
(Ser33, Ser37, Thr41 and Ser45)100. However, also other protein kinases, such 
as PKCα, have been described to directly phosphorylate β-catenin Ser/Thr 
residues in its N-terminal domain, inducing protein degradation101.  
We observed that metformin is able to downregulate β-catenin protein 
expression levels in all the endometrial cancer cell lines.  
Intriguingly, this effect is associated to the activation of PKCα, 
suggesting that metformin might inhibit the Wnt/β-catenin pathway in 
endometrial cancer cells. However, we observed that metformin attenuated 
GSK3β phosphorylation in the Ser 9 residue and this usually lead to an 
increase of β-catenin degradation rate75.  
Further experiments are currently ongoing in our laboratory to clarify 
whether GRP78 has a role in mediating the described effects and to understand 
whether PKCα action on β-catenin could be direct or indirect through the 
modulation of GSK3β activity. 
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6. CONCLUSIONS  
 
 
In sum, our data suggest that ER stress, the Unfolded Protein Response 
activation and altered GRP78 expression can play an important role in 
endometrial cancer. 
Based on these data, GRP78 might represent a new therapeutic target 
for the treatment of endometrial cancer. 
Interestingly, we describe also that metformin, an antidiabetic drug, 
inhibits the growth and migration of endometrial cancer cells, possibly through 
the downregulation of GRP78 and modulation of the UPR in apoptotic 
direction. 
Metformin effects on the UPR were accompanied to the inhibition of 
the β-catenin signaling pathway, possibly through the activation of PKCα. 
The eventual role of GRP78 in these effects are currently object of 
investigation in our laboratory.  
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